Panitumumab

Last updated
Panitumumab
Monoclonal antibody
Type Whole antibody
Source Human
Target Epidermal growth factor receptor (EGFR)
Clinical data
Trade names Vectibix
Other namesABX-EGF
AHFS/Drugs.com Monograph
MedlinePlus a607066
License data
Routes of
administration 		Intravenous
ATC code
Legal status
Legal status
  • US: WARNING [1] Rx-only [2]
  • EU:Rx-only [3]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life ~9.4 days (range: 4-11 days)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
Formula C6398H9878N1694O2016S48
Molar mass 144324.12 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans). [2] [3]

Contents

Panitumumab is manufactured by Amgen and was originally developed by Abgenix Inc.

In 2014, Amgen and Illumina entered into an agreement to develop a companion diagnostic to accompany panitumumab. [4]

Medical uses

Panitumumab was approved by the U.S. Food and Drug Administration (FDA) for the first time in September 2006, for "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite prior treatment. [5] Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008, for "the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS".

Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.

Contraindications

Panitumumab does not work in patients who have KRAS or NRAS mutations. [6]

Adverse effects

Panitumumab has been associated with skin rash, fatigue, nausea, diarrhea, fever, and decreased magnesium levels. Often, skin rash is noted in the sun exposed parts of the body, such as the face or chest. Oral antibiotics may be needed for worsening skin rash, such as one accompanied with blisters and ulcers. Otherwise, topical steroid creams like hydrocortisone may help. [7]

Ocular toxicity or keratitis was observed in 16% of patients on panitumumab, usually necessitating the discontinuance of therapy. [8]

In clinical trials, 90% of patients had dermatological toxicities and 15% of those were severe. Because of this, panitumumab has a boxed warning cautioning patients. Skin toxicities were typically apparent two weeks after beginning treatment. More severe skin toxicities were associated with improved progression free survival and overall survival. [8]

Pulmonary fibrosis and interstitial lung disease were observed in clinical trials. [8]

Pharmacology

Mechanism of action

EGFR is a transmembrane protein. Panitumumab works by binding to the extracellular domain of the EGFR preventing its activation. This results in halting of the cascade of intracellular signals dependent on this receptor. [9]

Pharmacokinetics

The pharmacokinetics (PK) of panitumumab shows the so-called target-mediated disposition behavior. [10] However, the pharmacokinetics is approximately linear at clinical doses, and the terminal half-life for a typical male patient of 80 kg and 60 years of age with colorectal cancer is about 9.4 days.[ medical citation needed ]

History

Panitumumab was generated using Abgenix's XenoMouse platform technology, in which engineered mice were utilized to produce human antibodies. Abgenix partnered with Immunex Corporation to develop the antibody, and Amgen acquired Immunex in 2003. In 2006, Amgen acquired Abgenix as well. In 2013, Amgen formed an agreement with Zhejiang Beta Pharma to form Amgen Beta Pharmaceuticals and market panitumumab in China. Amgen and Takeda have an agreement under which Takeda will develop and commercialise panitumumab in Japan. [11] Panitumumab is licensed to Dr Reddys Laboratories in India and GlaxoSmithKline in the UK.[ citation needed ]

FDA approval

Panitumumab was initially approved on September 27, 2006, for EGFR-expressing, metastatic CRC with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing regimens, based on the results of a study which showed clinical benefit in metastatic colorectal cancer patients. [12] In July 2009, the FDA updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include information about KRAS mutations. [13] This was the result of a study, which demonstrated lack of benefit with Panitumumab in patients who carried NRAS mutations. [6]

It is also approved as a first-line agent in combination with FOLFOX. [8]

Research

Panitumumab is being studied in numerous phase II and III clinical trials. Phase III clinical trials include treatment of esophageal cancer, [14] urothelial carcinoma, [15] metastatic head and neck cancer, [16] and liver metastasis in colorectal cancer. [17] Early trials showed limited efficacy in patients with malignant melanoma, bladder cancer, prostate cancer, and renal cell carcinoma. [11]

Panitumumab vs. cetuximab

Although they both target the EGFR, panitumumab (IgG2) and cetuximab (IgG1) differ in their isotype and they might differ in their mechanism of action. Monoclonal antibodies of the IgG1 isotype may activate the complement pathway and mediate antibody-dependent cellular cytotoxicity (ADCC). [18] It is not clear at this time, if one drug is superior to the other. In one of the studies, both these drugs were noted to be similar in activity. [19]

Related Research Articles

<span class="mw-page-title-main">Cetuximab</span> Pharmaceutical drug

Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology.

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

Adecatumumab (MT201) is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule, with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen.

<span class="mw-page-title-main">KRAS</span> Protein-coding gene in humans

KRAS is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus. These signals instruct the cell to grow and divide (proliferate) or to mature and take on specialized functions (differentiate). It is called KRAS because it was first identified as a viral oncogene in the KirstenRAt Sarcoma virus. The oncogene identified was derived from a cellular genome, so KRAS, when found in a cellular genome, is called a proto-oncogene.

<span class="mw-page-title-main">Ipilimumab</span> Pharmaceutical drug

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Matuzumab is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania

<span class="mw-page-title-main">Bi-specific T-cell engager</span>

Bi-specific T-cell engagers (BiTEs) are a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells' cytotoxic activity, against cancer cells. BiTE is a registered trademark of Micromet AG.

Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors.

Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer, Phase II trials for colorectal cancer, non-small cell lung cancer, and ovarian cancer have been completed.

Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).

Angiokinase inhibitors are a new therapeutic target for the management of cancer. They inhibit tumour angiogenesis, one of the key processes leading to invasion and metastasis of solid tumours, by targeting receptor tyrosine kinases. Examples include nintedanib, afatinib and motesanib.

<span class="mw-page-title-main">Brigatinib</span> ALK inhibitor for treatment of non-small-cell lung cancer

Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc. Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

Urelumab is a fully human, non‐ligand binding, CD137 agonist immunoglobulin‐γ 4 (IgG4) monoclonal antibody. It was developed utilizing Medarex's UltiMAb(R) technology by Bristol-Myers Squibb for the treatment of cancer and solid tumors. Urelumab promotes anti-tumor immunity, or an immune response against tumor cells, via CD137 activation. The application of Urelumab has been limited due to the fact that it can cause severe liver toxicity.

<span class="mw-page-title-main">Pembrolizumab</span> Pharmaceutical drug used in cancer treatment

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is administered by slow intravenous injection.

<span class="mw-page-title-main">PD-1 and PD-L1 inhibitors</span> Class of anticancer drugs

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells. Immune checkpoint inhibitors are emerging as a front-line treatment for several types of cancer.

MM-151 is an oligoclonal mixture of fully human monoclonal antibodies, which binds multiple parts of the EGFR molecule It has started clinical trials in patients with RAS wild-type colorectal cancers (CRCs) that were resistant to other anti-EGFR therapies. It is intended to overcome the problem of cancers becoming resistant to monoclonal antibody therapies.

Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.

Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and mesenchymal–epithelial transition (MET) receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

References

  1. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 Oct 2023.
  2. 1 2 "Vectibix- panitumumab solution". DailyMed. 25 August 2021. Archived from the original on 6 April 2022. Retrieved 6 July 2022.
  3. 1 2 "Vectibix EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 13 August 2021. Retrieved 6 July 2022.
  4. ↑ "Illumina, Amgen to Develop CDx for Colorectal Cancer". News: Molecular Diagnostics. Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. February 15, 2014. p. 32. Archived from the original on September 19, 2016. Retrieved December 2, 2014.
  5. ↑ "Drug Approval Package: Vectibix NDA #125147". U.S. Food and Drug Administration (FDA). 29 May 2007. Archived from the original on 31 March 2021. Retrieved 6 July 2022.
  6. 1 2 Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. (September 2013). "Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer". The New England Journal of Medicine. 369 (11): 1023–34. doi: 10.1056/NEJMoa1305275 . PMID   24024839. S2CID   14556160.
  7. ↑ Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. (March 2010). "Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer". Journal of Clinical Oncology. 28 (8): 1351–7. doi:10.1200/JCO.2008.21.7828. PMID   20142600. S2CID   30651519.
  8. 1 2 3 4 "UpToDate". Archived from the original on 2017-02-02. Retrieved 2017-01-27.
  9. ↑ Plunkett, Jack W. (September 30, 2005). Plunkett's Biotech & Genetics Industry Almanac 2006. Plunkett Research. ISBN   978-1-59392-033-3.[ page needed ]
  10. ↑ Ma P, Yang BB, Wang YM, Peterson M, Narayanan A, Sutjandra L, et al. (October 2009). "Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors". Journal of Clinical Pharmacology. 49 (10): 1142–56. doi:10.1177/0091270009344989. PMID   19723673. S2CID   25766549.
  11. 1 2 "Panitumumab - Amgen". AdisInsight. Archived from the original on 2017-11-03. Retrieved 2017-01-27.
  12. ↑ Gibson TB, Ranganathan A, Grothey A (May 2006). "Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer". Clinical Colorectal Cancer. 6 (1): 29–31. doi:10.3816/CCC.2006.n.01. PMID   16796788.
  13. ↑ "FDA updates Vectibix and Erbitux labels with KRAS testing info". 20 July 2009. Archived from the original on 3 March 2016. Retrieved 2 December 2014.[ unreliable medical source? ]
  14. ↑ Clinical trial number NCT01627379 for "Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer" at ClinicalTrials.gov
  15. ↑ Clinical trial number NCT00460265 NCT00460265 for "I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations" at ClinicalTrials.gov
  16. ↑ Clinical trial number NCT00460265 NCT00460265 for "Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer" at ClinicalTrials.gov
  17. ↑ Clinical trial number NCT02162563 for "Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases" at ClinicalTrials.gov
  18. ↑ HealthValue: IgG1 & IgG2 Archived 2019-06-05 at the Wayback Machine [ unreliable medical source? ]
  19. ↑ Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. (May 2014). "Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study". The Lancet. Oncology. 15 (6): 569–79. doi:10.1016/S1470-2045(14)70118-4. hdl: 2381/43402 . PMID   24739896.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.